Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

Summary

This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo. For this, the impact of CSJ117 on disease symptom burden and lung function will be explored.

Timeline

Start

2021-09-24

Primary completion

2022-09-15

Completion

2022-09-15

Publications

• Chow MYT, Pan HW, Lam JKW. Delivery technology of inhaled therapy for asthma and COPD. Adv Pharmacol. 2023;98:273-311. doi: 10.1016/bs.apha.2023.03.001. Epub 2023 Mar 28.

Drugs

Indications